Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: full-pipeline trial registry
1 of 2 indexed Polyradiculoneuropathy, Chronic Inflammatory Demyelinating trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 2 US clinical trials tracked, 1 recruiting.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 1 of these trials.
Enrollment posture brief
Registry condition polyradiculoneuropathy-chronic-inflammatory-demyelinating
OPEN 1 | RECR 50% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Janssen Research & Development
NCT05327114
Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CSL Behring
NCT02027701
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Polyradiculoneuropathy, Chronic Inflammatory Demyelinating records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Polyradiculoneuropathy, Chronic Inflammatory Demyelinating trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Polyradiculoneuropathy, Chronic Inflammatory Demyelinating page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Polyradiculoneuropathy, Chronic Inflammatory Demyelinating trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Polyradiculoneuropathy, Chronic Inflammatory Demyelinating condition card totals 2 registered trials; most-linked intervention IgPro20; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.